300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Theatre
Art
Real Estate
Medical
Sporting Goods
Recruiting
Manufacturing
Digital Media
FinTech
Finance
Web3
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Kyrgyzstan
Zimbabwe
Zambia
Norway
LATAM
Tajikistan
Africa
Mexico
Nigeria
Oceania
Russian Federation
Togo
Guinea
Iran
Nepal
Madagascar
Isle of Man
Pakistan
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Dan Suesskind, Director at Jerusalem Foundation

Dan Suesskind

Director @ Jerusalem Foundation

Dan Suesskind is a seed investor at Jerusalem Foundation focused on Men's and Medical. Dan S. Suesskind joined Israel Corp.’s Board in November 2011. He currently serves as a director of several companies, including Teva, Migdal Insurance Company Ltd. and Syneron Medical Ltd., as well as a member of the board (and finance and investment committee) of the Jerusalem Foundation, a member of the Investment Committee of the Israell Academy of Science and Humanities and the Board of Trustees of the Hebrew University. Prior to joining Teva’s Board in January 2010, he was Teva’s Chief Financial Officer from 1977 until 2008. He also served as a director of Teva from 1981 to 2001. From 2004 to 2011 he was a director of Ness Technologies Inc. He is one of the founders and a member of the steering committee of the Israeli Forum of Chief Financial Officers.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries Dan Suesskind invests in

Men'sMedicalHealth Care

Stages Dan Suesskind invests in

Seed

Countries Dan Suesskind invests in

Israel

Investment Focus

Industry

  • Men's 1 (100%)
  • Medical 1 (100%)
  • Health Care 1 (100%)

Investments

CompanyDescriptionRoundLinks
Butterfly Medical Butterfly Medical
Butterfly Medical is a medical-device start-up that aims to improve the standard of care for men suffering from Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has developed a fast, simple and minimally invasive alternative treatment to first-line BPH medication and surgery. Butterfly Medical’s patented device can beplaced in under 10 minutes, in-office, under local anesthesia, without surgical incision, heating or prostate tissue removal. The device aims to be the only in-office BPH treatment that delivers a long-term, effective solution with minimal side effects, requiring no hospitalization or general anesthesia. Early results from clinical trials are very promising with blocked urethras successfully opened and patients suffering no side effects. Further clinical studies are starting in leading medical centers in Europe.Visit www.butterfly-medical.com for more information. $2M / Seed / Jan 29, 2020
Jerusalem Foundation

About Jerusalem Foundation

VC Fund

Jerusalem Foundation Contacts

NameEmailPhoneSocials
Dan Suesskind
Dan Suesskind Director

Sign up to unlock verified contacts

Unlock Contacts

4 more contacts available

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Theatre
Art
Real Estate
Medical
Sporting Goods
Recruiting
Manufacturing
Digital Media
FinTech
Finance
Web3
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Kyrgyzstan
Zimbabwe
Zambia
Norway
LATAM
Tajikistan
Africa
Mexico
Nigeria
Oceania
Russian Federation
Togo
Guinea
Iran
Nepal
Madagascar
Isle of Man
Pakistan
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Dan Suesskind invest in?

Dan Suesskind invests primarily in Men's, Medical and Health Care startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Dan Suesskind last invest?

The most recent investment recorded for Dan Suesskind closed in Jan 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Dan Suesskind Dan Suesskind Find email